Eduard Johannes Van Beers

List of Publications by Year
in descending order

106	2,026	218592	276775
papers	citations	26 h-index	41 g-index

106	106	106	2024
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. Blood Advances, 2022, 6, 1844-1853.	2.5	12
2	Comment on: Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia. British Journal of Haematology, 2022, , .	1.2	0
3	Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, openâ€label study. American Journal of Hematology, 2022, 97, .	2.0	21
4	Mitapivat versus Placebo for Pyruvate Kinase Deficiency. New England Journal of Medicine, 2022, 386, 1432-1442.	13.9	42
5	Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase <scp>III</scp> placeboâ€controlled randomized crossâ€over clinical trial. American Journal of Hematology, 2022, 97, 924-932.	2.0	5
6	Oxygen gradient ektacytometryâ€derived biomarkers are associated with vasoâ€occlusive crises and correlate with treatment response in sickle cell disease. American Journal of Hematology, 2021, 96, E29-E32.	2.0	21
7	A remarkable case of HbH disease illustrates the relative contributions of the Î±-globin enhancers to gene expression. Blood, 2021, 137, 572-575.	0.6	6
8	Comorbidities and complications in adults with pyruvate kinase deficiency. European Journal of Haematology, 2021, 106, 484-492.	1.1	17
9	A Unique Monocyte Transcriptome Discriminates Sickle Cell Disease From Other Hereditary Hemolytic Anemias and Shows the Particular Importance of Lipid and Interferon Signaling. HemaSphere, 2021, 5, e531.	1.2	2
10	Effects of Genotypes and Treatment on Oxygenscan Parameters in Sickle Cell Disease. Cells, 2021, 10, 811.	1.8	10
11	Dried blood spot metabolomics reveals a metabolic fingerprint with diagnostic potential for Diamond Blackfan Anaemia. British Journal of Haematology, 2021, 193, 1185-1193.	1.2	4
12	Methodological aspects of oxygen gradient ektacytometry in sickle cell disease: Effects of sample storage on outcome parameters in distinct patient subgroups. Clinical Hemorheology and Microcirculation, 2021, 77, 391-394.	0.9	10
13	Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy. Blood, 2021, 137, 2997-3001.	0.6	22
14	Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in sickle cell disease. American Journal of Hematology, 2021, 96, E315-E318.	2.0	1
15	Metabolic Fingerprint in Hereditary Spherocytosis Correlates With Red Blood Cell Characteristics and Clinical Severity. HemaSphere, 2021, 5, e591.	1.2	2
16	Comparisons of oxygen gradient ektacytometry parameters between sickle cell patients with or without Î±â€thalassaemia. British Journal of Haematology, 2021, 195, 629-633.	1.2	3
17	Untargeted metabolic profiling in dried blood spots identifies disease fingerprint for pyruvate kinase deficiency. Haematologica, 2021, 106, 2720-2725.	1.7	14
18	A Comprehensive Analysis of the Erythropoietin-erythroferrone-hepcidin Pathway in Hereditary Hemolytic Anemias. HemaSphere, 2021, 5, e627.	1.2	1

#	Article	IF	Citations
19	Pharmacodynamic Effects of AG-946, a Highly Potent Next-Generation Activator of Pyruvate Kinase, in Ex Vivo Treatment of Red Blood Cells from Sickle Cell Disease Patients. Blood, 2021, 138, 2029-2029.	0.6	3
20	Identification of Biomarkers That Are Associated with Clinical Complications of Hemoglobin SC Disease and Sickle Cell Anemia. Blood, 2021, 138, 962-962.	0.6	2
21	Safety and Efficacy of Mitapivat (AG-348), an Oral Activator of Pyruvate Kinase R, in Subjects with Sickle Cell Disease: A Phase 2, Open-Label Study (ESTIMATE). Blood, 2021, 138, 2047-2047.	0.6	4
22	Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained over Time in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat in a Long-Term Extension Study. Blood, 2021, 138, 848-848.	0.6	1
23	Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias. Therapeutic Advances in Hematology, 2021, 12, 204062072110660.	1.1	31
24	Methodological aspects of the oxygenscan in sickle cell disease: A need for standardization. American Journal of Hematology, 2020, 95, E5-E8.	2.0	18
25	Characterization of the severe phenotype of pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, E281.	2.0	8
26	Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia. Blood Advances, 2020, 4, 1678-1682.	2.5	13
27	AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes. Haematologica, 2020, 106, 238-249.	1.7	45
28	Genotypeâ€phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, 472-482.	2.0	47
29	Liver Iron Retention Estimated from Utilization of Oral and Intravenous Radioiron in Various Anemias and Hemochromatosis in Humans. International Journal of Molecular Sciences, 2020, 21, 1077.	1.8	2
30	The variable manifestations of disease in pyruvate kinase deficiency and their management. Haematologica, 2020, 105, 2229-2239.	1.7	30
31	A Proposed Concept for Defective Mitophagy Leading to Late Stage Ineffective Erythropoiesis in Pyruvate Kinase Deficiency. Frontiers in Physiology, 2020, 11, 609103.	1.3	7
32	Red Cell Rheology Biomarkers to Assess Cure in Gene-Based Therapies. Blood, 2020, 136, 11-12.	0.6	0
33	Oxygen Gradient Ektacytometry-Derived Biomarkers Are Associated with the Occurrence of Cerebral Infarction, Acute Chest Syndrome and Vaso-Occlusive Crisis in Sickle Cell Disease. Blood, 2020, 136, 20-21.	0.6	0
34	Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency. Blood, 2020, 136, 30-32.	0.6	3
35	Baseline Characteristics of Patients in Peak: A Global, Longitudinal Registry of Patients with Pyruvate Kinase Deficiency. Blood, 2020, 136, 39-40.	0.6	0
36	Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency. New England Journal of Medicine, 2019, 381, 933-944.	13.9	115

#	Article	IF	Citations
37	Sickle cell disease: Clinical presentation and management of a global health challenge. Blood Reviews, 2019, 37, 100580.	2.8	42
38	The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research. Frontiers in Physiology, 2019, 10, 304.	1.3	33
39	Clinical Remission of Deltaâ€Aminolevulinic Acid Dehydratase Deficiency Through Suppression of Erythroid Heme Synthesis. Hepatology, 2019, 70, 434-436.	3.6	11
40	Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients. American Journal of Hematology, 2019, 94, 575-584.	2.0	47
41	Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry. Journal of Visualized Experiments, 2019, , .	0.2	9
42	The Complexity of Genotypeâ€Phenotype Correlations in Hereditary Spherocytosis: A Cohort of 95ÂPatients. HemaSphere, 2019, 3, e276.	1.2	43
43	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica, 2019, 104, e51-e53.	1.7	46
44	Organ involvement occurs in all forms of hereditary haemolytic anaemia. British Journal of Haematology, 2019, 185, 602-605.	1.2	2
45	Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. American Journal of Hematology, 2019, 94, 149-161.	2.0	55
46	Proton Pump Inhibition for Secondary Hemochromatosis in Hereditary Anemia, a Phase III Placebo Controlled Randomized Cross-over Trial in Progress. Blood, 2019, 134, 960-960.	0.6	11
47	Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency. Blood, 2019, 134, 949-949.	0.6	0
48	An Ongoing Global, Longitudinal, Observational Study of Patients with Pyruvate Kinase Deficiency: The PEAK Registry. Blood, 2019, 134, 2223-2223.	0.6	1
49	Erythropoietin Is Associated with a Decline in the iFGF23/cFGF23 Ratio in Patients with Various Hereditary Hemolytic Anemias. Blood, 2019, 134, 4793-4793.	0.6	0
50	Mitapivat (AG-348) in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (ACTIVATE) in Progress. Blood, 2019, 134, 4791-4791.	0.6	0
51	A Unique Monocyte Transcriptome Discriminates Sickle Cell Disease from Other Hereditary Hemolytic Anemias and Shows the Particular Importance of Lipid and Interferon Signaling. Blood, 2019, 134, 980-980.	0.6	0
52	Decreased Activity and Stability of Pyruvate Kinase in Hereditary Hemolytic Anemia: A Potential Target for Therapy By AG-348 (Mitapivat), an Allosteric Activator of Red Blood Cell Pyruvate Kinase. Blood, 2019, 134, 3506-3506.	0.6	6
53	Lactate Dehydrogenase to Carboxyhemoglobin Ratio As a Biomarker of Heme Release to Heme Processing Is Associated with Higher Tricuspid Regurgitant Jet Velocity and Early Death in Sickle Cell Disease. Blood, 2019, 134, 2274-2274.	0.6	0
54	The Oxygenscan Provides Clinically Relevant Biomarkers for Treatment Efficacy That Are Associated with Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease. Blood, 2019, 134, 2275-2275.	0.6	0

#	Article	IF	Citations
55	Oxidative stress in sickle cell disease; more than a DAMP squib. Clinical Hemorheology and Microcirculation, 2018, 68, 239-250.	0.9	17
56	Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiency. Haematologica, 2018, 103, e82-e86.	1.7	42
57	Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood, 2018, 131, 2183-2192.	0.6	121
58	Haem augments and iron chelation decreases tollâ€like receptor 4 mediated inflammation in monocytes from sickle cell patients. British Journal of Haematology, 2018, 181, 552-554.	1.2	7
59	Iron overload in patients with rare hereditary hemolytic anemia: Evidenceâ€based suggestion on whom and how to screen. American Journal of Hematology, 2018, 93, E374-E376.	2.0	8
60	The Oxygenscan: A Rapid and Reproducible Test to Determine Patient-Specific, Clinically Relevant Biomarkers of Disease Severity in Sickle Cell Anemia. Blood, 2018, 132, 2360-2360.	0.6	1
61	Expression of the Human Alpha-Globin Cluster in the Absence of the Major Regulatory Element Mcs-R2. Blood, 2018, 132, 3632-3632.	0.6	1
62	Striking Difference in Iron Utilization between Oral and Intravenous Iron in Various Anemias and Hemochromatosis. Blood, 2018, 132, 2338-2338.	0.6	0
63	Phosphatidylserine-Exposing Extracellular Vesicles after Splenectomy Are Associated with Increased D-Dimers and Fibrin Generation in Hereditary Hemolytic Anemia. Blood, 2018, 132, 630-630.	0.6	0
64	Screening for hemosiderosis in patients receiving multiple red blood cell transfusions. European Journal of Haematology, 2017, 98, 478-484.	1.1	5
65	Prospective evaluation of chronic organ damage in adult sickle cell patients: A sevenâ€year followâ€up study. American Journal of Hematology, 2017, 92, E584-E590.	2.0	25
66	Haematological malignancy in the intensive care unit: microbiology results and mortality. European Journal of Haematology, 2016, 97, 271-277.	1.1	6
67	Sickle Cell Imaging Flow Cytometry Assay (SIFCA). Methods in Molecular Biology, 2016, 1389, 279-292.	0.4	11
68	Iron Overload Is Highly Prevalent in All Disease Severity States in Pyruvate Kinase Deficiency (PKD). Blood, 2016, 128, 2430-2430.	0.6	1
69	<scp>N</scp>â€terminal proâ€<scp>B</scp>â€type natriuretic peptide, tricuspid jet flow velocity, and death in adults with sickle cell disease. American Journal of Hematology, 2015, 90, E75-6.	2.0	8
70	Iron, Inflammation, and Early Death in Adults With Sickle Cell Disease. Circulation Research, 2015, 116, 298-306.	2.0	71
71	Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants. Blood, 2015, 126, 3337-3337.	0.6	4
72	Imaging flow cytometry for automated detection of hypoxiaâ€induced erythrocyte shape change in sickle cell disease. American Journal of Hematology, 2014, 89, 598-603.	2.0	60

#	Article	IF	Citations
73	Exercise tolerance, lung function abnormalities, anemia, and cardiothoracic ratio in sickle cell patients. American Journal of Hematology, 2014, 89, 819-824.	2.0	29
74	Imaging flow cytometry documents incomplete resistance of human sickle F-cells to ex vivo hypoxia-induced sickling. Blood, 2014, 124, 658-660.	0.6	6
75	The Anti-Sickling Agent Aes-103 Decreases Sickle Erythrocyte Fragility, Hypoxia-Induced Sickling and Hemolysis In Vitro. Blood, 2013, 122, 940-940.	0.6	4
76	Systematic Evaluation Of Chronic Organ Damage In Adult Sickle Cell Patients. A Seven-Year Follow-Up Study. Blood, 2013, 122, 4683-4683.	0.6	0
77	Chronic pulmonary embolism in Klippel-Trenaunay syndrome. Journal of the American Academy of Dermatology, 2012, 66, 71-77.	0.6	31
78	Effect of corruption on medical care in lowâ€income countries. Pediatric Blood and Cancer, 2012, 58, 325-326.	0.8	15
79	Imaging Flow Cytometry for Fully Automated Quantification of Percentage of Sickled Cells in Sickle Cell Anemia.. Blood, 2012, 120, 2105-2105.	0.6	1
80	Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia". Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 405-406.	0.7	3
81	Turnover of Heme-Bound Iron Is Associated with Activation of TLR4 and Chemokine Receptor Pathways in the Peripheral Blood Mononuclear Cell Transcriptome in Sickle Cell Anemia. Blood, 2012, 120, 819-819.	0.6	0
82	Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis. Blood Cells, Molecules, and Diseases, 2011, 46, 189-194.	0.6	18
83	Licorice consumption as a cause of posterior reversible encephalopathy syndrome: a case report. Critical Care, 2011, 15, R64.	2.5	23
84	Letter in response to: â€œPulmonary thrombi are not detected by 3D magnetic resonance angiography in adults with sickle cell anemia and an elevated triscuspid regurgitant jet velocityâ€. American Journal of Hematology, 2010, 85, 217-217.	2.0	0
85	Acute chest syndrome in sickle cell disease due to the new influenza A (H1N1) virus infection. American Journal of Hematology, 2010, 85, 303-304.	2.0	13
86	Pain rate and social circumstances rather than cumulative organ damage determine the quality of life in adults with sickle cell disease. American Journal of Hematology, 2010, 85, 532-535.	2.0	33
87	Extensive Slow-Flow Vascular Malformations and Pulmonary Hypertension. Archives of Dermatology, 2010, 146, 1416.	1.7	4
88	Dynamic Cerebral Autoregulation in Homozygous Sickle Cell Disease. Stroke, 2009, 40, 808-814.	1.0	30
89	Elevated endothelial progenitor cells during painful sickle cell crisis. Experimental Hematology, 2009, 37, 1054-1059.	0.2	10
90	Lung function tests in patients with sickle cell disease: A reply. American Journal of Hematology, 2009, 84, 310-311.	2.0	0

#	Article	IF	Citations
91	Do NSAIDs Actually Protect Against Myocardial Infarction and Death?. Clinical Pharmacology and Therapeutics, 2009, 86, 601-602.	2.3	5
92	Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica, 2009, 94, 1513-1519.	1.7	241
93	Cerebrovascular reserve capacity is impaired in patients with sickle cell disease. Blood, 2009, 114, 3473-3478.	0.6	63
94	Pain Rate and Social Circumstances Rather Than Cumulative Organ Damage Determine the Quality of Life in Adults with Sickle Cell Disease.. Blood, 2009, 114, 4605-4605.	0.6	0
95	Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension. American Journal of Hematology, 2008, 83, 850-854.	2.0	32
96	Normal sublingual microcirculation during painful crisis in sickle cell disease. Microvascular Research, 2008, 76, 57-60.	1.1	11
97	Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension. Haematologica, 2008, 93, 1410-1412.	1.7	22
98	No association of the hypercoagulable state with sickle cell disease related pulmonary hypertension. Haematologica, 2008, 93, e42-e44.	1.7	35
99	Large and Medium-Sized Pulmonary Artery Obstruction Does Not Play a Role of Primary Importance in the Etiology of Sickle-Cell Disease-Associated Pulmonary Hypertension. Chest, 2008, 133, 646-652.	0.4	23
100	Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice. Haematologica, 2008, 93, 757-760.	1.7	41
101	Sickle cell patients are characterized by a reduced glycocalyx volume. Haematologica, 2008, 93, 307-308.	1.7	9
102	Elevated Endothelial Progenitor Cells during Painful Sickle Cell Crisis. Blood, 2008, 112, 4796-4796.	0.6	0
103	Comment on: Kretowski et al. (2007) Polymorphisms of the Renin-Angiotensin System Genes Predict Progression of Subclinical Coronary Atherosclerosis: Diabetes 56:863-871. Diabetes, 2007, 56, e5-e5.	0.3	3
104	Patientâ€controlled analgesia versus continuous infusion of morphine during vasoâ€occlusive crisis in sickle cell disease, a randomized controlled trial. American Journal of Hematology, 2007, 82, 955-960.	2.0	105
105	Exercise Capacity and Pulmonary Function in Sickle Cell Patients with Pulmonary Arterial Hypertension.. Blood, 2006, 108, 3804-3804.	0.6	0
106	A Randomized Controlled Trial of Patient Controlled Analgesia Versus Continuous Infusion of Morphine during Vaso-Occlusive Crisis in Sickle Cell Disease.. Blood, 2005, 106, 3782-3782.	0.6	0